Agenda
Please note all sessions listed in Central Time. Agenda subject to change.
Thursday, April 15
Day 1
6:45 am
Registration Opens
7:15 am — 8:15 am
Breakfast & Non-CME/CE Bonus Presentation
8:15 am — 8:30 am
Exhibit & Poster Hall Opens
8:30 am — 8:40 am
Conference Welcome
8:40 am — 10:45 am
Session I: Advances in Myelodysplastic Syndromes and Precursor States
8:40 am — 8:45 am
Session Introduction
8:45 am — 9:05 am
We Should Start Therapy Prior to Transfusion Dependence in LR-MDS
9:05 am — 9:15 am
Audience Q&A
Rami Komrokji, MD
9:15 am — 9:35 am
What Can Spatial Transcriptomics Teach Us About Myelodysplastic Syndromes?
9:35 am — 9:45 am
Audience Q&A
Susan DeWolf, MD
9:45 am — 10:05 am
When To Include a Workup For Germline Predisposition States Like Short Telomere Syndrome or Other Germline States
10:05 am — 10:15 am
Audience Q&A
Christopher R. Reilly, MD
10:15 am — 10:35 am
Targeting the Inflammasome to Treat MDS
10:35 am — 10:45 am
Audience Q&A
Alan List, MD
10:45 am — 11:15 am
Break: Visit Exhibit & Poster Hall
11:15 am — 11:55 am
Stump the Experts: MDS & AML
MDS Fellow - Kian J. Rahbari, MD
AML Expert - Eunice S. Wang, MD
11:55 am — 1:30 pm
Session II: Pre-Clinical Translational Research
11:55 am — 12:00 pm
Session Introduction
12:00 pm — 12:20 pm
Modeling the Malignant Niche: 3D Systems and Spatial Biology in AM
12:20 pm — 12:30 pm
Audience Q&A
Iannis Aifantis, MD
12:30 pm — 12:50 pm
No More Marrows? Mapping Circulating Stem Cells in AML
12:50 pm — 1:00 pm
Audience Q&A
Liran I. Shlush, MD, PhD
1:00 pm — 1:20 pm
What’s the Leukemia Forecast: Predicting Relapse After Transplant
1:20 pm — 1:30 pm
Audience Q&A
Peter van Galen, PhD
1:30 pm — 2:30 pm
Lunch & Non-CME/CE Bonus Presentation
2:30 pm — 2:45 pm
Refreshment Break: Visit Exhibit & Poster Hall
2:45 pm — 3:50 pm
Session III: Novel Strategies in ALL
2:45 pm — 2:50 pm
Session Introduction
2:50 pm — 3:10 pm
Pearls and Pitfalls: Challenges and Opportunities of Blinatumomab
3:10 pm — 3:20 pm
Audience Q&A
Marlise R. Luskin, MD
3:20 pm — 3:40 pm
Pick Your Poison: Pivekimab vs Tagraxofusp for BPDCN
3:40 pm — 3:50 pm
Audience Q&A
Rita Assi, MD
3:50 pm — 4:05 pm
Break: Visit Exhibit & Poster Hall
4:05 pm — 5:40 pm
Session IV: Multidisciplinary Care
4:05 pm — 4:10 pm
Session Introduction
4:10 pm — 4:30 pm
From Snouts to Souls: How Palliative Pigs Caultivate Resilence, Joy and Purpose in Leukemia Care
4:30 pm — 4:40 pm
Audience Q&A
Krista Dobbie, MD
4:40 pm — 5:00 pm
Going PRO: Why (the right) Patient Outcomes Are Crucial for AML Studies
5:00 pm — 5:10 pm
Audience Q&A
5:10 pm — 5:30 pm
Best Practices for Evaluation of Elderly AML Patients for BMT Eligibility
5:30 pm — 5:40 pm
Audience Q&A
Reena V. Jayani-Kosarzycki, MD, MSCI
5:40 pm — 6:40 pm
Refreshments & Non-CME/CE Bonus Presentation
6:40 pm — 7:40 pm
Welcome Reception
7:40 pm
Day One Adjourns
Friday, April 16
Day 2
7:00 am
Registration Opens
7:15 am — 8:15 am
Breakfast & Non-CME/CE Bonus Presentation
8:15 am — 8:30 am
Exhibit & Poster Hall Opens
8:30 am — 8:35 am
Welcome Back
8:35 am — 10:10 am
Session V: Acute Myeloid Leukemia
8:35 am — 8:40 am
Session Introduction
8:40 am — 9:00 am
The Significance of Mutation Location in AML Prognostication
9:00 am — 9:10 am
Audience Q&A
Andrew Kent, MD, PhD
9:10 am — 9:30 am
Why Do We Need So Many Menin Inhibitors? Meaningful Clinical Differences (if any) Between Drugs
9:30 am — 9:40 am
Audience Q&A
Ghayas Issa, MD
9:40 am — 10:00 am
Dealing with Abundance: Should We Preferentially Target FLT3 When There Are Multiple Targetable Mutations (NPM1, IDH1/2)?
10:00 am — 10:10 am
Audience Q&A
Jessica Altman, MD
10:15 am — 11:15 am
Refreshments & Non-CME/CE Bonus Presentation
11:15 am — 11:45 am
Break: Visit Exhibit & Poster Hall
11:45 am — 12:45 pm
Session VI: Ernest Beutler Memorial Lecture
11:45 am — 11:55 pm
Introduction
11:55 am — 12:35 pm
Ernest Beutler Memorial Lecture
12:35 pm — 12:45 pm
Audience Q&A
Jacob M. Rowe, MD
12:45 pm — 1:45 pm
Lunch & Non-CME/CE Bonus Presentation
1:45 pm — 2:00 pm
Refreshment Break: Visit Exhibit & Poster Hall
2:00 pm — 3:45 pm
Session VII: Bone Marrow Transplant
2:00 pm — 2:05 pm
Session Introduction
2:05 pm — 2:25 pm
Don’t Be Late! Does the Timing of CAR-T Cell Therapy Influence Outcomes and Why?
2:25 pm — 2:35 pm
Audience Q&A
Roni Shouval, MD, PhD
2:35 pm — 2:55 pm
Does GVHD Remain a Significant Issue in Modern Day Bone Marrow Transplants?
2:55 pm — 3:05 pm
Audience Q&A
Javier Bolaños Meade, MD
3:15 pm — 3:35 pm
Should We Offer Allogeneic Stem Cell Transplants to Patients With Active Leukemia
3:35 pm — 3:45 pm
Audience Q&A
Lori Muffly, MD, MS
3:45 pm — 3:55 pm
Closing Remarks
3:55 pm
Conference Ends